The Quantellect read.As of Nov 19, 2026, 6 active firms cover Immunocore Holdings Ltd: 4 rate it Buy or better, 2 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $33.00 to $100.00 (about 3.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $58.00 sits 111% above the current $27.52. The rating mix has stayed broadly stable, with Buy-side ratings easing from 5 to 4 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.11 next quarter toward $-0.64 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 active firms
Buy
Strong Buy00%
Buy467%
Neutral233%
Sell00%
Strong Sell00%
Based on 6 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$58.00
+110.7% upside
Average target across 6 active firms as of Nov 19, 2026 vs $27.53 current
Highest Target$100.00
Average Target$58.00
Lowest Target$33.00
Detailed analyst forecasts for IMCR
Showing 1–6 of 6 named analysts shown · 6 active firms in the rating projection
As of Nov 19, 2026, 4 of 6 active firms rate IMCR a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
IMCR EPS & revenue forecast
EPS · NEXT QUARTER
$-0.11
Range $-0.22 – $-0.03 · 5 analysts · -145% YoY
Next period, 5 analysts expect Immunocore Holdings Ltd to earn $-0.11 a share (range $-0.22 – $-0.03), versus $0.25 a year earlier. Full-year consensus is $-0.20, growing to $-0.64 the year after.
REVENUE · NEXT QUARTER
$119.9M
Range $110.6M – $132.5M · 5 analysts · +12% YoY
Revenue is expected to reach $119.9M (range $110.6M – $132.5M), +12.4% year-over-year. Full-year consensus is $437.2M, rising to $480.5M next year.
Top analysts covering Immunocore Holdings Ltd
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IMCR.
#1
Peter Lawson
Barclays · Rank #89
Buy
$52.00+88.9% to target
Overall win rate
45%
+ Follow
#2
Jessica Fye
JP Morgan · Rank #100
Buy
$50.00+81.7% to target
Overall win rate
54%
+ Follow
#3
Graig Suvannavejh
Mizuho · Rank #239
Neutral
$35.00+27.2% to target
Overall win rate
40%
+ Follow
#4
Patrick R. Trucchio
HC Wainwright & Co. · Rank #308
Buy
$100.00+263.3% to target
Overall win rate
36%
+ Follow
#5
Jeff Jones
Oppenheimer · Rank #320
Buy
$86.00+212.4% to target
Overall win rate
32%
+ Follow
IMCR stock forecast FAQ
What is IMCR's average 12-month price target?+
The 6 active firms with a live target average $58.00 for Immunocore Holdings Ltd over the next 12 months, ranging from a $100.00 high to a $33.00 low, as of Nov 19, 2026.
Is IMCR stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 6 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for IMCR?+
The Street-high target is $100.00 (HC Wainwright & Co.), and the Street-low is $33.00 (Jefferies). The average of all 6 active-firm targets is $58.00.
How many active Wall Street firms cover IMCR?+
6 active firms have a recognized rating on Immunocore Holdings Ltd as of Nov 19, 2026, and 6 active firms carry a live 12-month price target.
Who is the most accurate analyst covering IMCR?+
Among analysts who currently cover IMCR, Peter Lawson of Barclays has the strongest overall Quantellect track record (Rank #89). Their current call is Buy with a $52.00 target.
What is Immunocore Holdings Ltd's projected EPS for next quarter?+
The consensus estimate is $-0.11 per share (range $-0.22 – $-0.03) across 5 analysts. Full-year EPS is projected at $-0.20, rising to $-0.64 the following year.
How much revenue is Immunocore Holdings Ltd expected to report next quarter?+
Consensus revenue is $119.9M (range $110.6M – $132.5M). Full-year revenue is projected at $437.2M, growing to $480.5M next year.
Have analysts been upgrading or downgrading IMCR lately?+
As of Nov 19, 2026, 4 of 6 active firms rate IMCR a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IMCR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.